利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

67 条记录 (耗时 0.03 秒)

    DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK
    1.
    发明申请
    DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK 审中-公开
    诊断心血管危险因素的诊断

    公开(公告)号：US20160146834A1

    公开(公告)日：2016-05-26

    申请号：US14904423

    申请日：2014-07-11

    申请人： EMORY UNIVERSITY

    发明人： Arshed A. QUYYUMI

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2333/4737 ,  G01N2333/70596 ,  G01N2333/75 ,  G01N2333/9723 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/60 ,  G01N2800/7004 ,  G01N2800/7095

    摘要： This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), urokinase or urokinase receptor (uPA/uPAR), and/or anti-CMV antibody.

    摘要翻译： 本发明涉及心血管疾病的领域，具体涉及使用标记物的组合来预测个体发展冠状动脉疾病（CAD）和相关疾病如心绞痛和外周血管疾病的风险的诊断测试方法，以及更多 特别是确定个体的心肌梗塞，死亡和中风的风险。 示例性生物标志物包括C反应蛋白（CRP），纤维蛋白降解产物（FDP），热休克蛋白70（HSP70），尿激酶或尿激酶受体（uPA / uPAR）和/或抗CMV抗体。

    ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES
    2.
    发明申请
    ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES 审中-公开
    基于体液活化剂体系中分子激活因子分析水平的癌症患者监测的测定

    公开(公告)号：US20120220524A1

    公开(公告)日：2012-08-30

    申请号：US13407641

    申请日：2012-02-28

    申请人： Walter P. Carney ,  Peter J. Hamer

    发明人： Walter P. Carney ,  Peter J. Hamer

    IPC分类号： A61K38/22 ,  A61P35/00

    CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

    摘要： The present invention describes methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. An increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression.

    摘要翻译： 本发明描述了随时间的检查，筛选和监测正在接受治疗或治疗的癌症患者的结果的方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 正常对照个体中相应的PA系统分析物中的一种或多种水平与癌症患者中的一种或多种PA系统分析物水平的增加或升高相关，作为癌症进展或进展的指标。

    Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples
    3.
    发明申请
    Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples 审中-公开
    基于体液样品中纤溶酶原激活物系统分析物成分水平的癌症患者监测分析

    公开(公告)号：US20090286268A1

    公开(公告)日：2009-11-19

    申请号：US12507737

    申请日：2009-07-22

    申请人： Walter P. Carney ,  Peter J. Hamer

    发明人： Walter P. Carney ,  Peter J. Hamer

    IPC分类号： G01N33/53

    CPC分类号： G01N33/57484 ,  G01N33/86 ,  G01N2333/8132 ,  G01N2333/9723 ,  G01N2800/52 ,  Y10T436/25

    摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.

    摘要翻译： 本发明描述临床和医学上重要的随时间的检查，筛选和监测正在接受治疗或治疗他或她的疾病的癌症患者的结果的重要方法。 更具体地，本发明提供了通过测量纤溶酶原激活物（uPA）系统的一种或多种分析物的水平，即uPA，PAI-1，在癌症患者中监测疾病进展或癌症治疗的有效性的方法， 1和来自癌症患者的样品中的uPA：PAI-1的复合物，优选在治疗前，治疗开始时和治疗期间的各个时间间隔。 作为执行该方法的结果，癌症患者中的一种或多种PA系统分析物的水平的增加或升高与正常对照个体中相应的PA系统分析物中的一个或多个水平相比作为 癌症进展或进展和/或患者缺乏治疗有效性。

    METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION
    4.
    发明申请
    METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION 审中-公开
    鉴定癌症生物标志物和癌症进展的方法

    公开(公告)号：US20090208980A1

    公开(公告)日：2009-08-20

    申请号：US12434928

    申请日：2009-05-04

    申请人： Benjamin Yat Ming Yung

    发明人： Benjamin Yat Ming Yung

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57407 ,  G01N33/57484 ,  G01N2333/9723 ,  G01N2800/56

    摘要： An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma.

    摘要翻译： 提供了使用pro-u-PA作为临床工具识别重要癌症生物标志物并鉴定膀胱癌进展的有效方法。 首先分析了高度恶性的U1和前恶性U4细胞系分泌的蛋白质组，寻找膀胱癌诊断和预后关键的生物标志物。 通过与MALDI-TOF质谱联用的SDS-PAGE系统检测U1和U4细胞系培养基中的蛋白质。 通过蛋白质印迹分析证实原纤维蛋白溶酶原激活物（pro-u-PA）的表达，进一步评估。 建立了具有高阶段和等级的肿瘤样本的尿液中低水平和缺乏pro-u-PA之间的统计学显着性关系。 Ras显性阴性蛋白的组成型表达导致培养基中pro-u-PA的表达增加，表明pro-u-PA的损失与致癌转化相关。 尿中pro-u-PA的损失已被确定为更晚期膀胱癌的标志物。

    Molecular-specific urokinase antibodies
    5.
    发明授权
    Molecular-specific urokinase antibodies 有权
    分子特异性尿激酶抗体

    公开(公告)号：US07541159B2

    公开(公告)日：2009-06-02

    申请号：US10828531

    申请日：2004-04-14

    申请人： M. Zouhair Atassi ,  Dennis R. Morrison

    发明人： M. Zouhair Atassi ,  Dennis R. Morrison

    IPC分类号： G01N33/573 ,  G01N33/577

    CPC分类号： G01N33/86 ,  G01N2333/9723

    摘要： Antibodies have been developed against the different molecular forms of urokinase using synthetic peptides as immunogens. The peptides were synthesized specifically to represent those regions of the urokinase molecules which are exposed in the three-dimensional configuration of the molecule and are uniquely homologous to urokinase. Antibodies are directed against the lysine 158-isoleucine 159 peptide bond which is cleaved during activation from the single-chain (ScuPA) form to the bioactive double chain (54 KDa and 33 KDa) forms of urokinase and against the lysine 135 lysine 136 bond that is cleaved in the process of removing the alpha-chain from the 54 KDa form to produce the 33 KDa form of urokinase. These antibodies enable the direct measurement of the different molecular forms of urokinase from small samples of conditioned medium harvested from cell cultures.

    摘要翻译： 已经使用合成肽作为免疫原，针对不同分子形式的尿激酶开发了抗体。 合成肽特异性地代表在分子的三维构型中暴露的与尿激酶唯一同源的尿激酶分子的那些区域。 抗体针对赖氨酸158-异亮氨酸159肽键，其在从单链（ScuPA）形式到生物活性双链（54KDa和33KDa）形式的尿激酶和赖氨酸135赖氨酸136键的活化期间被切割 在从54KDa形式除去α链以产生33KDa形式的尿激酶的过程中被切割。 这些抗体能够从细胞培养物收获的条件培养基的小样本直接测量不同分子形式的尿激酶。

    Molecular-specific urokinase antibodies
    6.
    发明申请
    Molecular-specific urokinase antibodies 有权
    分子特异性尿激酶抗体

    公开(公告)号：US20050233397A1

    公开(公告)日：2005-10-20

    申请号：US10828531

    申请日：2004-04-14

    申请人： M. Atassi ,  Dennis Morrison

    发明人： M. Atassi ,  Dennis Morrison

    IPC分类号： G01N33/53 ,  G01N33/537 ,  G01N33/543 ,  G01N33/86

    CPC分类号： G01N33/86 ,  G01N2333/9723

    摘要： Antibodies have been developed against the different molecular forms of urokinase using synthetic peptides as immunogens. The peptides were synthesized specifically to represent those regions of the urokinase molecules which are exposed in the three-dimensional configuration of the molecule and are uniquely homologous to urokinase. Antibodies are directed against the lysine 158-isoleucine 159 peptide bond which is cleaved during activation from the single-chain (ScuPA) form to the bioactive double chain (54 KDa and 33 KDa) forms of urokinase and against the lysine 135 lysine 136 bond that is cleaved in the process of removing the alpha-chain from the 54 KDa form to produce the 33 KDa form of urokinase. These antibodies enable the direct measurement of the different molecular forms of urokinase from small samples of conditioned medium harvested from cell cultures.

    摘要翻译： 已经使用合成肽作为免疫原，针对不同分子形式的尿激酶开发了抗体。 合成肽特异性地代表在分子的三维构型中暴露的与尿激酶唯一同源的尿激酶分子的那些区域。 抗体针对赖氨酸158-异亮氨酸159肽键，其在从单链（ScuPA）形式到生物活性双链（54KDa和33KDa）形式的尿激酶和赖氨酸135赖氨酸136键的活化期间被切割 在从54KDa形式除去α链以产生33KDa形式的尿激酶的过程中被切割。 这些抗体能够从细胞培养物收获的条件培养基的小样本直接测量不同分子形式的尿激酶。